TB-500

TB-500 is a trade name used in the research-peptide market. FDA's 2026 review describes TB-500 (free base) as a seven-amino-acid fragment of thymosin beta-4, with an N-terminal acetyl group, and treats TB-500 acetate as a separate substance. It is sold here for laboratory research use only.

FDA's review describes TB-500 (free base) as a short fragment (amino acids 17–23) of the 43-amino-acid thymosin beta-4 molecule. Full-length thymosin beta-4 is the distinct parent peptide. This confirms the trade name's general identity as FDA understands it, but does not by itself confirm what this specific listing's material is.

No. FDA describes TB-500 (free base) as a short 7-amino-acid fragment, while full-length thymosin beta-4 is a separate 43-amino-acid peptide. Research on the full-length molecule should not be assumed to apply to the fragment, or to this specific product, without further confirmation.

Published studies on this mechanism, such as Xue et al. (2014) and Malinda et al. (1999), examined full-length thymosin beta-4 in cell culture and animal wound models, not the TB-500 fragment by name. These are in-vitro and animal observations, not demonstrated outcomes in people.

Philp et al. (2004) reported that thymosin beta-4 promoted angiogenesis, new blood vessel formation, in rodent models. This describes a research finding in a specific animal model, not a therapeutic effect in humans, and it concerns full-length thymosin beta-4 rather than the TB-500 fragment specifically.

No. Animal wound-healing results are specific to the species and model used. FDA's own 2026 review found no evidence of TB-500 having been administered to humans at all, so animal findings for thymosin beta-4 cannot be treated as evidence for human use of this product.

It reports how much of a sample is the intended peptide relative to total detected material, a measure of cleanliness. It does not independently establish molecular identity, biological potency, sterility, endotoxin status, or stability.

A useful COA identifies the batch or lot, the testing method, the analyte and result, and the laboratory responsible for the analysis, and it should match the material being described rather than a generic or unrelated document.

No. Neither TB-500 (free base) nor TB-500 acetate is a component of an FDA-approved drug. FDA staff reviewing the compound for the 503A Bulks List recommended against adding it, citing a lack of human safety data; its Pharmacy Compounding Advisory Committee then voted in favor of recommending it anyway at its July 2026 meeting. That vote is non-binding, concerns compounding eligibility rather than drug approval, and still requires further FDA rulemaking.

No. A product labeled for research use only is not automatically equivalent to an FDA-approved prescription medicine. An RUO disclaimer does not, by itself, establish regulatory compliance; the product's overall presentation and intended-use claims still matter.